Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Applied Therapeutics (APLT) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $2.0 million.

  • Applied Therapeutics' Total Non-Current Liabilities rose 1909.78% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 1909.78%. This contributed to the annual value of $2.4 million for FY2024, which is 19974.91% up from last year.
  • As of Q3 2025, Applied Therapeutics' Total Non-Current Liabilities stood at $2.0 million, which was up 1909.78% from $2.2 million recorded in Q2 2025.
  • Over the past 5 years, Applied Therapeutics' Total Non-Current Liabilities peaked at $2.4 million during Q4 2024, and registered a low of $30000.0 during Q2 2024.
  • For the 3-year period, Applied Therapeutics' Total Non-Current Liabilities averaged around $1.3 million, with its median value being $825000.0 (2023).
  • As far as peak fluctuations go, Applied Therapeutics' Total Non-Current Liabilities tumbled by 9621.21% in 2024, and later soared by 708333.33% in 2025.
  • Over the past 3 years, Applied Therapeutics' Total Non-Current Liabilities (Quarter) stood at $797000.0 in 2023, then surged by 199.75% to $2.4 million in 2024, then dropped by 14.9% to $2.0 million in 2025.
  • Its Total Non-Current Liabilities stands at $2.0 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.3 million for Q1 2025.